Evaluation of Intestinal Parasites in Patients With Intestinal Cancer in Sohag, Egypt.

November 24, 2023 updated by: Nagwa Ibrahim Selim, Sohag University
This study aims to evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Intestinal parasitic infections continue to be characterized as a significant cause of morbidity worldwide, and according to World Health Organization (WHO) statistics, more than a quarter of the world's population, mostly in developing countries, are infected Acquisition of infection, clinical severity, and outcome of a parasitic disease depend on innate and acquired host immunity as well as on the parasite's response against the host when the infection is established Chronic infections and inflammation along with unhealthy diet, stressful lifestyle, cell damage, constant exposure to radiation, and harmful chemicals are risk factors for the development of cancers As infectious factors, the Blastocystis hominis and Cryptosporidium spp. are opportunistic protozoa isolated from the human host gastrointestinal tract, These prevalent enteric parasites may cause serious challenges in people undergoing colorectal cancer treatment (chemotherapy)

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Case-control study

Description

Inclusion Criteria:

  • intestinal cancer patients (colorectal cancer, intestinal lymphoma, gastrointestinal stromal tumors, and other malignant variants)

Exclusion Criteria:

  • patient took antibiotics within the previous four weeks and anti-parasitic drugs within the previous two weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
group A
• One hundred stool samples will be collected from patients with intestinal cancer admitted to Sohag Hospital.
Diagnostic test: stool examination
Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
group B
one hundred stool samples will be collected from the control group of patients who attended outpatient clinics
Diagnostic test: stool examination
Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals
Time Frame: 12 months
• Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Study Director: nada a elnady, professor, Sohag University
  • Study Chair: emad e nabil, ass prof, Sohag University
  • Study Chair: manal r gaballah, lecturer, Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 30, 2023

Primary Completion (Estimated)

April 30, 2024

Study Completion (Estimated)

May 30, 2024

Study Registration Dates

First Submitted

April 30, 2023

First Submitted That Met QC Criteria

April 30, 2023

First Posted (Actual)

May 9, 2023

Study Record Updates

Last Update Posted (Actual)

November 27, 2023

Last Update Submitted That Met QC Criteria

November 24, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-23-04-24MS_

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intestinal Parasites in Patients With Intestinal Cancer

Clinical Trials on stool examination

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe